DrugPatentWatch Database Preview
Drugs in Development Information for Sotrastaurin
Drug Development Status for Sotrastaurin: Patents, clinical trial progress, indications
Sotrastaurin is an investigational drug.
There have been 6 clinical trials for Sotrastaurin.
The most recent clinical trial was a Phase 2 trial, which was initiated on April 1st 2010.
The most common disease conditions in clinical trials are Uveal Neoplasms, Melanoma, and Lymphoma, Mantle-Cell. The leading clinical trial sponsors are Novartis Pharmaceuticals, Array BioPharma, and James Blachly.
There are eighteen US patents protecting this investigational drug and two hundred and forty-seven international patents.
Summary for Sotrastaurin
| US Patents | 18 |
| International Patents | 247 |
| US Patent Applications | 45 |
| WIPO Patent Applications | 34 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2010-04-01) |
| Vendors | 42 |
Recent Clinical Trials for Sotrastaurin
| Title | Sponsor | Phase |
|---|---|---|
| Trial of AEB071 in Combination With BYL719 in Patients With Melanoma | Richard D. Carvajal | Phase 1 |
| A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma | Array BioPharma | Phase 1/Phase 2 |
| Efficacy, Safety, Tolerability, Pharmacokinetics of Sotrastaurin-tacrolimus vs. Mycophenolic Acid-tacrolimus in de Novo Liver Transplant Patients | Novartis Pharmaceuticals | Phase 2 |
Clinical Trial Summary for Sotrastaurin
Top disease conditions for Sotrastaurin
Top clinical trial sponsors for Sotrastaurin
US Patents for Sotrastaurin
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Sotrastaurin | See Pricing | Stem cell modulation II | University of Canberra (Bruce, Australian Capital Territory, AU) | See Pricing |
| Sotrastaurin | See Pricing | Indolylmaleimide derivatives | Novartis AG (Basel, CH) | See Pricing |
| Sotrastaurin | See Pricing | Indolylmaleimide derivatives | Novartis AG (Basel, CH) | See Pricing |
| Sotrastaurin | See Pricing | Indolylmaleimide derivatives | See Pricing | |
| Sotrastaurin | See Pricing | Indolylmaleimide derivatives | See Pricing | |
| Sotrastaurin | See Pricing | Drug monitoring assay | Novartis AG (Basel, CH) | See Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Sotrastaurin
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Sotrastaurin | Australia | 2014324092 | 2033-09-18 | See Pricing |
| Sotrastaurin | Canada | 2923765 | 2033-09-18 | See Pricing |
| Sotrastaurin | China | 105764513 | 2033-09-18 | See Pricing |
| Sotrastaurin | European Patent Office | 3046560 | 2033-09-18 | See Pricing |
| Sotrastaurin | Japan | 2016537400 | 2033-09-18 | See Pricing |
| Sotrastaurin | Singapore | 11201601408P | 2033-09-18 | See Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
